Dermanolon 1.77 mg/ml + 17.7 mg/ml Cutaneous Spray, Solution for Dogs and Cats

Nazione: Regno Unito

Lingua: inglese

Fonte: VMD (Veterinary Medicines Directorate)

Principio attivo:

Salicylic Acid, Triamcinolone Acetonide

Commercializzato da:

Le Vet Beheer B.V.

Codice ATC:

QD07XB02

INN (Nome Internazionale):

Salicylic Acid, Triamcinolone Acetonide

Forma farmaceutica:

Cutaneous spray, solution

Tipo di ricetta:

POM-V - Prescription Only Medicine – Veterinarian

Gruppo terapeutico:

Cats, Dogs

Area terapeutica:

Anti Inflammatory corticosteroid

Stato dell'autorizzazione:

Authorized

Data dell'autorizzazione:

2017-01-27

Scheda tecnica

Revised: January 2022
AN: 00461/2021 & 00464/2021
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Dermanolon 1.77 mg/ml + 17.7 mg/ml cutaneous spray, solution for dogs
and cats
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCES:
Triamcinolone acetonide
1.77 mg
Salicylic acid
17.7 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Cutaneous spray, solution.
Clear colourless solution.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs and cats.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Symptomatic treatment of seborrhoeic dermatitis
4.3
CONTRAINDICATIONS
Do not use in cases of hypersensitivity to corticosteroids, salicylic
acid or to any of
the excipients
Do not use on cutaneous ulcers.
Do not use in dogs with demodicosis.
Do not administer to animals weighing less than 3.5 kg body weight.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
At the beginning of treatment, existing scale and or exfoliative
debris should be
removed. Hair surrounding or covering the lesions may need to be
clipped to enable
the veterinary medicinal product to reach the affected skin.
Seborrhoeic dermatitis may be a primary disorder, but can also occur
as a result of
underlying disorders or disease processes (e.g. allergic disorders,
endocrine
disorders, neoplasia). Furthermore, infections (bacterial, parasitic
or fungal)
Revised: January 2022
AN: 00461/2021 & 00464/2021
Page 2 of 5
commonly occur concurrently with seborrhoeic dermatitis. Therefore it
is essential to
identify any underlying disease process and initiate specific
treatment if considered
necessary.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
As the minimum bodyweight for the treatment is 3,5 kg, this product
will not be
suitable for use in certain patients, such as smaller dogs and cats or
those with
extensive lesions. Please check maximum recommended dose in section
4.9.
Systemic corticosteroid effects are possible, especially when the
product is u